Major stock indexes closed sharply higher Friday, but nevertheless posted weekly losses on concerns about AI spending and ...

Since May 2025, Insulet has been in a holding pattern, posting a small return of 3% while floating around $335.74. The stock ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting results this Thursday before market hours. Here’s what investors should know. Insulet beat analysts’ revenue expectations ...

Fintel reports that on November 13, 2025, BTIG reiterated coverage of Insulet (NasdaqGS:PODD) with a Buy recommendation. Analyst Price Forecast Suggests 9.18% Upside As of November 9, 2025, the ...

As of November 9, 2025, the average one-year price target for Insulet is $367.77/share. The forecasts range from a low of $303.00 to a high of $420.00. The average price target represents an increase ...

Insulet (NASDAQ:PODD) has outperformed the market over the past 15 years by 10.68% on an annualized basis producing an average annual return of 22.81%. Currently, Insulet has a market capitalization ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Preferred Bank PFBC: This banking products and services company has seen the Zacks Consensus Estimate for its current year ...

Insulet also expects in 2028 to release the Omnipod Fully Closed Loop for Type 2, which will automate insulin delivery for patients with type 2 diabetes. It said the out-of-the-box product will be the ...

Insulet (PODD) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $0.9 per share a year ago. These figures are ...

Insulet Corporation ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company's global ...